This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that VICTRELIS
® (boceprevir) 200 mg Capsules, the company’s oral treatment for chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin has received the Prix Galien USA Award for Best Pharmaceutical Agent.
The Prix Galien USA Award recognizes the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices. It is considered the biomedical industry’s highest accolade.
"Merck is honored to have been chosen as a recipient of this prestigious award," said Peter S. Kim, president of Merck Research Laboratories. "This achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring VICTRELIS to market.”
The Prix Galien Award recognizes the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally recognized award, the Prix Galien was founded in France in 1969 by French pharmacist, Roland Mehl and is considered the highest accolade for pharmaceutical research and development.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.